
    
      Part 1 is a randomised, double-blind, placebo-controlled, SAD study with a food effect
      assessment.

      Part 2 is a randomised, double-blind, placebo controlled, MAD study over 14 days. In order to
      explore the potential CYP3A4 inducer effect, midazolam will also be administered in one
      cohort.

      Part 3 is a 3-period, open label, randomised, sequential study. Each subject will receive
      solid dose formulation and powder for oral suspension in a randomised manner.
    
  